Thus, our results together establish that circulating LIF concentration and LIF abundance in clinical samples are promising prognostic biomarkers and LIF/LIFR/STAT3 axis is a druggable target with translational potentials in HNSCC. The gene discussed is LIFR; the disease is head and neck squamous cell carcinoma.